Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Local Thai Drug Makers Urging Compulsory Licensing “Ill-Informed” – PReMA President

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Local Thai drug makers are urging the Thai government to issue compulsory licenses for three patented cancer drugs, saying the licenses are legal and would benefit Thailand, the Bangkok Post reported

You may also be interested in...



Thailand’s Public Health Minister Asked To Step Down For Failing To Report Shareholdings

PERTH, Australia - Thailand's Public Health Minister Chaiya Sasomsab may have to step down from his post after failing to report his wife's shareholdings in a company, according to the Bangkok Post

Thailand’s Public Health Minister Asked To Step Down For Failing To Report Shareholdings

PERTH, Australia - Thailand's Public Health Minister Chaiya Sasomsab may have to step down from his post after failing to report his wife's shareholdings in a company, according to the Bangkok Post

Thai FDA Head “Surprised” By Health Minister’s Decision To Remove Him From Post – PharmAsia News Interview

PERTH, Australia - One of the main architects of the previous Thai government's compulsory license policy, FDA head Siriwat Tiptaradol told PharmAsia News that he does not know why the country's Public Health Minister Chaiya Sasomsab removed him from his post

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel